Using lab-grown human cells, RPB-supported researchers at The Johns Hopkins University indicate that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to...
The idea that stem cells – the precursors of all body tissues – could be turned into organ replacements for diseased body parts has tantalized physicians and patients for decades.
March 24, 2015, Washington, DC -- Top execs from major eye research funding organizations convened in Washington, DC for a second time to advance an agenda for collaborative action in addressing key issues facing...
On May 19, Research to Prevent Blindness was present in Washington, DC, along with other organizations supporting the major Institute of Medicine study "Public Health Approaches to Reduce Vision Impairment and...
Human corneal tissue is highly organized in a structure which contributes to its transparency. Corneal scarring caused by injury, infections or genetic diseases, can create permanent vision loss. ...
RPB-supported researchers at the University of Southern California (USC) report that ranibizumab (sold as Lucentis) can help Hispanic and non-Hispanic whites with diabetic macular edema (DME) in the United States...
Entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health," the report, to be released in 2016, will examine core principles and public health strategies to reduce visual...
Research to Prevent Blindness (RPB) is rolling out a new category of grants designed to foster collaboration between scientists working within departments of ophthalmology and those in complementary...
Research to Prevent Blindness (RPB) is partnering with the International Retinal Research Foundation (IRRF) to advance knowledge about age-related macular degeneration (AMD) through novel stem cell research. ...
New York, NY, December, 2014 -- With the approval of 33 new grants to individual scientists and 24 grants to departments of ophthalmology, Research to Prevent Blindness (RPB), the leading foundation supporting eye...
HIV/AIDS drugs that have been used for the last 30 years could be used to treat age-related macular degeneration (AMD), according to a study partially supported by unrestricted funds from RPB. The researchers...
Larry Hester, 66, has been blind for half his life from retinitis pigmentosa. In September, 2014, an electronic stimulator called the Argus 2 (developed, in part, with RPB support) was surgically implanted in his...
Click here for photo identification. Photo ID includes links to all attendees' web sites.Research to Prevent Blindness hosted a convening of nearly two dozen organizations committed to the advancement of eye...
"We can now give hope to patients who previously had no hope. Although the federal investment in the NEI provides seed funding for potential breakthroughs, we need private philanthropy and industry to invest...
The endowment will enable the University of Alabama Birmingham department of ophthalmology to recruit a world-class scientist to join its existing roster of international experts in the study of blinding diseases...
Age-related macular degeneration (AMD), which is characterized by choroidal neovascularization (CNV), or blood vessel growth, is the primary cause of blindness in elderly individuals of industrialized countries. The...
In January of 2014, National Eye Institute director Dr. Paul Sieving accepted a bust of Dr. Jules Stein on behalf of the NEI. The bust, created by renowned Cubist sculptor Jacques Lipchitz, was a gift from RPB. Dr....
According to RPB Special Scholar Awardee Dr. Valeria Canto-Soler, Johns Hopkins University School of Medicine: "We have basically created a miniature human retina in a dish that not only has the architectural...
A new study offers an explanation for how years of chronic sunlight exposure can increase the risk of cataract, a clouding of the eye lens that typically occurs with aging. The study firms up a link between the...
RPB is doubling its annual support of amblyopia research and honoring an esteemed donor, the late Diane Disney Miller. Amblyopia, commonly referred to as "lazy eye," is the major cause of monocular...
RPB is providing $500,000 to accelerate the development of treatments for Retinitis Pigmentosa (RP) -- a family of retinal diseases that progressively create extreme tunnel vision, loss of night vision and leave...
For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial, funded jointly by RPB and the National Eye Institute, suggests that for most...
Compared to earlier generations, today's generation has a 50% reduced probability of losing sight to glaucoma 20 years after a diagnosis, according to research supported by RPB.Read the story.Read the...
For more on the impact of vision loss, read RPB's recent newsletter. RPB-supported research shows that patients with visual field loss from glaucoma travel less than those with normal vision,curtail...
RPB-supported researchers have demonstrated that a new type of contact lens can deliver a therapeutic amount of a glaucoma drug every day for a month. The breakthrough, which has been pursued for decades, may...
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Research Scientists & Grantees | Eye Care Specialists | Donors & Partners |